Loading
VB
Valion Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Apr 2026.
Valion Bio, Inc.: what insiders have been doing
Valion Bio, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 8 filings came from 5 insiders.
Only purchases show up on the open market, 2 purchases in all worth €24k, filed by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €16k, the purchase published on 2 April 2026 by Valauri Christina Rizopoulos is the largest of the period. The buyers include 2 senior executives.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 181 days ago, on 20 April 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 8 filings, this issuer sits below that mark. Since 2021, the database holds 2 purchases and no sales by insiders of the company.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€24,344
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleChristina Rizopoulos Valauri1 buy
Sheryle Bolton1 buy
Since the insiders bought
- -68.9%Entry 29.00 · Close at T+90 9.02
- -48.6%Entry 24.25 · Close at T+90 12.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 24 September 2026
Declarations11 total
2 shares@ US$2.12100.0% of flowCommon StockSEC:0001683168-26-007396:1
4 sharesCommon StockSEC:0001683168-26-007396:0
10,000 shares@ US$1.040.25% mcap100.0% of flowCommon StockSEC:0001683168-26-003073:0
Canonical exit: 14 Jul 2026 (T+90)
19,000 shares@ US$0.9478100.0% of flowCommon StockSEC:0001683168-26-002599:0
Canonical exit: 30 Jun 2026 (T+90)
92 sharesCommon StockSEC:0001683168-26-002034:0
8,824 sharesCommon StockSEC:0001683168-26-001220:0
736 sharesCommon StockSEC:0001683168-25-009306:0
14,706 sharesCommon StockSEC:0001683168-25-009305:0
22,541 shares0Common StockSEC:0001683168-25-007223:0
7,500 shares0Common StockSEC:0000950170-24-035557:0
1,391 shares0Common StockSEC:0001104659-21-139507:0
11 of 11 declarations
About Valion Bio, Inc.
Valion Bio, Inc. is a company listed on the XNAS market, specializing in the development of biopharmaceutical solutions. It focuses on innovation in the field of biological treatments.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
